相似文献
1
Enterprising pharmacists use Medicare card to lower costs for health system, patients.
Am J Health Syst Pharm. 2004 Dec 1;61(23):2462, 2465-6, 2472. doi: 10.1093/ajhp/61.23.2462.
2
States on the Front Line: Addressing America's Drug Pricing Problem.
J Leg Med. 2019 Apr-Jun;39(2):81-93. doi: 10.1080/01947648.2019.1645544.
3
Medicare prescription drug legislation: how would it affect beneficiaries?
Policy Brief Commonw Fund. 2003 Oct(678):1-12.
4
Public payers foot greater pharmacy costs.
Manag Care. 2006 Jul;15(7):70.
5
Where are we, how did we get here, where are we going?
Med Care. 1995 Jan;33(1 Suppl):JS3-7; discussion JS7-12. doi: 10.1097/00005650-199501001-00002.
6
State model: Washington. Managed competition and premium caps in Washington State.
Health Aff (Millwood). 1993 Summer;12(2):82-8. doi: 10.1377/hlthaff.12.2.82.
7
Redefining Medicare's long-term financial health: a closer look at the "Medicare funding warning" in the trustees' report.
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)). 2004 Jun(IB67):1-4.
8
Affordable prescription drugs for NC consumers: the next challenge.
N C Med J. 2003 Nov-Dec;64(6):298-9.
9
AMCP Guide to Pharmaceutical Payment Methods.
J Manag Care Pharm. 2007 Oct;13(8 Suppl C):S1-39.
10
Selling cost containment.
Am J Law Med. 1993;19(1-2):95-119.
Zotero 插件